Pharmaceutical Sales Forecasting | Build reliable and effective forecasts
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
Trusted commercial intelligence, consensus forecasts, news and analysis for pharma, biotech and medtech industry - Explore Evaluate| Evaluate
Learn how to improve pharmaceutical sales forecasting accuracy. Discover methods, data sources, and eventing techniques to create reliable sales forecasts in pharma.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
Biotechs sponsor a growing share of new drugs & many are commercializing their products too. What are the steps to successful biotech commercialization?| Evaluate
Insmed CEO Will Lewis talked to Evaluate about the biotech’s orphan drug strategy, why it is still committed to rare diseases, and how orphan drug benefits might be better targeted.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
